Xenomics, Inc. is the developer of next-generation molecular diagnostics products that address important health problems worldwide. They apply proprietary transrenal DNA test platform to develop highly sensitive, truly non-invasive molecular diagnostics that replace outdated blood, sputum, and tissue testing technologies many of which are not sufficiently sensitive and specific, and are often hazardous, and difficult to automate.
The patented technology uses simple urine specimens and can be applied to a broad range of products addressing multi-billion dollar markets including infectious disease detection and monitoring, cancer detection and monitoring, prenatal genetic testing, monitoring organ/cell transplants, human forensics, and biodefense.
2007-02-23
02:04:31
·
2 answers
·
asked by
Jason S
1